文献速递神经肌肉病

吉兰-巴雷综合征当前治疗实践:国际GBS结局研究首批1300例分析

Current treatment practice of Guillain-Barré syndrome.
PubMed 文献 · Neurology · 2019-06-07

基于国际GBS结局研究(IGOS)首批1300例前瞻性观察数据,描述GBS总体及不同亚型的治疗实践。排除88例后,剩余1023例中941例(92%)接受了IVIg、PE或其他免疫治疗;严重型97%、轻型75%、Miller Fisher综合征76%、其他变异型83%接受治疗。初始治疗未改善者中35%接受二次免疫调节治疗,5%出现治疗相关波动,其中68%再治疗。结论:轻型、变异型及治疗失败/波动患者常被治疗,但缺乏试验证据支持。

要点

  • GBS总体免疫治疗率92%,严重型97%、轻型75%、Miller Fisher综合征76%、其他变异型83%。
  • 初始治疗未改善者中35%接受二次免疫调节治疗。
  • 治疗相关波动发生率5%,其中68%再接受IVIg或PE治疗。

核心结论

  • 当前实践中,轻型、变异型GBS及治疗失败或波动患者常接受治疗,但缺乏试验证据支持。
  • 治疗实践的差异部分源于缺乏针对这些情况的证据和指南。

研究设计与样本

  • 基于国际GBS结局研究(IGOS)首批1300例患者的前瞻性观察数据。
  • 排除88例(7%)后,对剩余1023例分析治疗实践,并按严重型、未恢复、治疗相关波动、轻型及变异型分层。
  • 孟加拉国189例(15%)因83%未治疗而单独描述。

主要发现

  • 941/1023(92%)接受IVIg、PE或其他免疫治疗。
  • 严重GBS(不能独立行走)724/743(97%)接受治疗,轻型GBS(能独立行走)126/168(75%)。
  • Miller Fisher综合征53/70(76%)和其他变异型33/40(83%)接受治疗。
  • 初始治疗后未改善的235例(32%)中,82例(35%)接受第二次免疫调节治疗。
  • 1023例中53例(5%)出现治疗相关波动,其中36例(68%)再接受IVIg或PE治疗。

临床怎么用

  • 严重GBS患者绝大多数接受免疫治疗,符合当前实践。
  • 轻型、变异型及治疗失败或波动患者也常被治疗,但需认识到缺乏试验证据支持。
  • 治疗决策应考虑患者特征和医院类型,并注意治疗实践的差异。

局限性

  • 排除88例(7%)因数据缺失、方案违背或替代诊断。
  • 孟加拉国患者因83%未治疗而单独描述,可能影响总体治疗率的代表性。
  • 观察性设计无法评估治疗与结局的因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To define the current treatment practice of Guillain-Barré syndrome (GBS). METHODS: The study was based on prospective observational data from the first 1,300 patients included in the International GBS Outcome Study. We described the treatment practice of GBS in general, and for (1) severe forms (unable to walk independently), (2) no recovery after initial treatment, (3) treatment-related fluctuations, (4) mild forms (able to walk independently), and (5) variant forms including Miller Fisher syndrome, taking patient characteristics and hospital type into account. RESULTS: We excluded 88 (7%) patients because of missing data, protocol violation, or alternative diagnosis. Patients from Bangladesh (n = 189, 15%) were described separately because 83% were not treated. IV immunoglobulin (IVIg), plasma exchange (PE), or other immunotherapy was provided in 941 (92%) of the remaining 1,023 patients, including patients with severe GBS (724/743, 97%), mild GBS (126/168, 75%), Miller Fisher syndrome (53/70, 76%), and other variants (33/40, 83%). Of 235 (32%) patients who did not improve after their initial treatment, 82 (35%) received a second immune modulatory treatment. A treatment-related fluctuation was observed in 53 (5%) of 1,023 patients, of whom 36 (68%) were re-treated with IVIg or PE. CONCLUSIONS: In current practice, patients with mild and variant forms of GBS, or with treatment-related fluctuations and treatment failures, are frequently treated, even in absence of trial data to support this choice. The variability in treatment practice can be explained in part by the lack of evidence and guidelines for effective treatment in these situations.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Verboon C, Doets AY, Galassi G, et al. Current treatment practice of Guillain-Barré syndrome. Neurology. 2019. PMID: 31175208. doi:10.1212/WNL.0000000000007719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。